Abstract Background Medications targeting the glucagon-like peptide-1 (GLP-1) pathway are an important therapeutic class currently used for the treatment of Type 2 diabetes (T2D)
Through the lawsuit, Kansas City aims to recover expenses associated with environmental testing, regulatory compliance, site remediation, and future upgrades to protect drinking water infrastructure
Effects of GLP-1RAs on Specific Inflammatory Skin Diseases While research is still ongoing, early indications are that GLP-1s may offer benefits for inflammatory skin diseases, including: Psoriasis immune dysregulation related to T cells and cytokines leads to systemic inflammation, skin discoloration, and thickening plaques
Again, evidence is primarily animal-based, not FDA approved
But you should be aware that your weight loss journey will be much slower than people who have a thyroid
Canada communicable disease report = Releve des maladies transmissibles au Canada, 49(9):375379